Pneumococcal conjugate second or third-dose vaccines (PCVc) in Algeria
Algeria: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 95.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Algeria, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Algeria is 95.0%, measured in 2025. That is the highest value across all 18 years on record.
The figure is up 5.6% on the previous year and up 14.5% over five years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Algeria peaked at 95.0% in 2025 and was at its lowest, 0.0%, in 2008.
That places Algeria 38th out of 194 countries with data for 2025, putting it in the top quarter.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Algeria, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 61.0% | — |
| 2017 | 89.0% | +45.9% |
| 2018 | 91.0% | +2.2% |
| 2019 | 87.0% | -4.4% |
| 2020 | 83.0% | -4.6% |
| 2021 | 78.0% | -6.0% |
| 2022 | 74.0% | -5.1% |
| 2023 | 89.0% | +20.3% |
| 2024 | 90.0% | +1.1% |
| 2025 | 95.0% | +5.6% |
Algeria compared with similar countries
- Algeria's 95.0% is above the median for upper middle income countries, which is 76.0%, 1.2× the median. (57 countries reporting)
- Algeria's 95.0% is above the median for Middle East, North Africa, Afghanistan & Pakistan, which is 91.0%, 1.0× the median. (23 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 32.8% | 0.0% | 91.0% | 10 |
| 2020s | 84.8% | 74.0% | 95.0% | 6 |
Countries ranked near Algeria
More health data for Algeria
- Un projection of annual infant deaths, annual growth rate -1.82 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.5437 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 943.1 deaths per 1,000 people (2090)
- Number of infants who die before age 1 1,455 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -2.77 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0465 units per person (2025)
- Population ages 00-04, male, annual growth rate -2.77 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Algeria?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Algeria was 95.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Algeria?
- The highest recorded value was 95.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Algeria?
- The lowest recorded value was 0.0% in 2008.
- How does Algeria rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Algeria ranks 38th out of 194 countries with data for 2025.
- Where does this Algeria data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).